1. Switzerland Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Addex Therapeutics Ltd

Addex Therapeutics Ltd

0.02
CHF
+0.00
(+1.80%)
-0.06EPS
4.61MMarket Cap
Nov 09Next Earn
Addex Therapeutics Ltd
SIX:ADXN
(SIX Swiss Exchange)

Recent

price

0.02

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
CHF
0.33
0.38
- -
- -
- -
- -
- -
- -
0.26
0.1
0.14
0.09
0.03
0.02
- -
- -
- -
Revenue per Share
-5.69
-4.19
-3.36
-1.6
-0.18
-0.39
-0.28
-0.25
-0.07
-0.56
-0.48
-0.45
-0.46
-0.14
0.07
-0.06
-0.06
Basic EPS, GAAP
-5.37
-3.6
-3.76
-1.74
-0.18
-0.24
-0.24
-0.17
0.07
-0.36
-0.46
-0.43
-0.36
-0.11
-0.05
-0.02
-0.02
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
10.17
4.15
1.66
0.31
0.23
0.15
0.02
0.1
1.49
0.96
0.54
0.45
0.06
0.01
0.1
0.04
0.03
Book Value per Share
10.16
4.14
1.65
0.3
0.23
0.15
0.02
0.1
1.49
0.96
0.54
0.45
0.06
0.01
0.1
0.04
0.03
Tangible Book Value per Share
6
7
8
9
10
11
11
13
23
26
27
34
45
74
98
107
112
Basic Weighted Avg Shares
2
3
- -
- -
- -
- -
- -
- -
6
3
4
3
1
2
- -
- -
- -
Sales/Revenue/Turnover
-1,700.93
-1,097.02
- -
- -
- -
- -
- -
- -
-23.58
-528.59
-338.88
-531.7
-741.04
-139.06
-681.82
-9,390.76
-8,968.91
Operating Margin (%)
3
3
2
1
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Depreciation Expense
-34
-31
-27
-14
-2
-4
-3
-3
-2
-15
-13
-15
-21
-11
7
-7
-7
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
-1,703.33
-1,102.95
- -
- -
- -
- -
- -
- -
-27.21
-534.98
-355.92
-526.42
-1,462.57
-654.47
1,746.04
-22,448.44
-23,245.44
Profit Margin (%)
57
29
12
2
1
2
- -
2
40
27
16
18
5
1
3
- -
- -
Working Capital
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
LT Debt
64
32
14
3
2
2
- -
1
39
26
15
17
5
1
10
5
3
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
-47.39
-64.62
-115
-166.79
-66.08
-209.69
-334.54
-420.26
-8.11
-45.64
-64.08
-97.35
-190.48
-348.48
130.39
-93.16
-120.31
Return on Common Equity (%)

Capital Structure

CHF

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
117
118
119
Market Capitalization
8
7
5

Working Capital

CHF

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
2
2
1
Cash, Cash Equivalents & STI
2
2
1
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
1
1
1
Payables & Accruals
1
1
1
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

CHF

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
373.48%
112.46%
-50.74%
Free Cash Flow
-92.82%
-22.36%
-59.61%
Net Income, GAAP
35.83%
-71.31%
-195.36%
Sales/Revenue/Turnover
- -
-44.93%
-92.58%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

CHF

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

CHF

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.03
0.13
-0.02
-0.01
0.07
2025
-0.01
-0.02
-0.01
-0.02
-0.06
2026
-0.01
- -
- -
- -
- -

Quarterly Dividends Per Share

CHF

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Addex Therapeutics Ltd, a clinical-stage biopharmaceutical company headquartered in Geneva, Switzerland and founded in 2002, discovers, develops and commercializes small-molecule allosteric modulators for neurological disorders; its lead product candidate dipraglurant, an mGlu5 negative allosteric modulator (NAM), advances in Phase 2a trials for Parkinson's disease levodopa-induced dyskinesia (PD-LID) and prepares for registration trials in PD-LID while also targeting post-stroke/TBI recovery and brain injury; ADX71149, an mGlu2 positive allosteric modulator (PAM), operates in Phase 2 readiness following rights regain from Janssen Pharmaceuticals for repositioning in mild neurocognitive disorders, schizophrenia and anxious depression; the preclinical pipeline encompasses GABAB PAM for pain, overactive bladder, substance use disorder (licensed to Indivior PLC) and chronic cough; mGlu7 NAM for post-traumatic stress disorder; mGlu2 NAM for treatment-resistant depression and cognitive deficits; mGlu4 PAM for Parkinson's disease; mGlu3 PAM for neurodegenerative disorders; and M4 PAM programs. The company conducts operations primarily from Switzerland with global partnerships and listings on the SIX Swiss Exchange (ADXN.SW) and Nasdaq (ADXN). In recent developments, Addex sold its allosteric modulator drug discovery platform and select preclinical programs to Neurosterix Pharma in April 2024, securing a 20% equity stake in the spin-out focused on schizophrenia, mood and neurocognitive therapies; regained full rights to ADX71149 after Janssen's 2025 discontinuation of the epilepsy program; entered a partnership with Sinntaxis for dipraglurant's brain injury indication; and reported CHF2.8 million in cash as of Q1 2025 to support pipeline advancement and new collaborations.

Company News

Company News APIChatGPT

  • globenewswire.com

    Addex GABAB PAM Candidate Demonstrates Robust Anti-Tussive Activity in Non-Human Primate Chronic Cough Model

  • globenewswire.com

    Addex Therapeutics Reports 2025 Third Quarter Financial Results and Provides Corporate Update